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ABSTRACT
Atopic dermatitis, or eczema, is an inflammatory skin disease resulting in dry, red, and itchy skin
that affects almost 20% of the population of the Western world. This disease creates a physical, emotional,
as well as financial burden on those affected, as well as their families. Current treatment options are only
somewhat effective, and do not have a long duration of release and therefore efficiency. Furthermore,
treatment plans involving corticosteroids need to be closely regulated to monitor side effects such as skin
thinning. Other options include topical tacrolimus, emollients, and oral antihistamines, each with varied
side effects. This project is then aimed to correct this inconsistency, by creating a transdermal drug delivery
method that utilizes a novel polymeric nanoparticle to encapsulate hydrocortisone. This will be achieved
by first generating a Chitosan nanoparticle that is small enough to enter the layers of the skin, then solvating
this nanoparticle in ionic liquid as a transdermal permeation enhancer, and administering it to skin. The end
goal would be for the nanoparticle to embed under the skin and slowly degrade at a tuned rate, thus allowing
for a sustained and supervised drug release of up to a week.
In pursuing this project, the target particle size for Chitosan nanoparticles was achieved, a modified
PEG solution was created, and the two came together to produce a nanoparticle that could be solvated
successfully in ionic liquid without aggregation. This compound was administered in an ex vivo pig skin
model to test delivery efficiency, using Rhodamine dye in the nanoparticles themselves to track delivery
efficacy. It was shown that the nanoparticles do reach the intended layers of the skin, and ionic liquid is
needed for transdermal transport. Future investigation of this project will require a means of actually
encapsulating hydrocortisone into the nanoparticles, and the development and use of in vivo diseased rat
models .
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CHAPTER 1: INTRODUCTION

Atopic dermatitis (AD), also known as eczema, is a medical condition that results in red and itchy
skin. It is most common in children but can occur at any age, typically presenting itself before age five.
This condition is chronic and tends to flare periodically over the lifespan, possibly being accompanied by
asthma or hay fever. Symptoms of this condition can include, but are not limited to: dry skin, itching, red
to brownish-gray patches, small and raised bumps, and sensitive or swollen skin. There is currently no cure
for AD, and the failings of current treatment methods are therefore the focus of this research project (1).
AD affects up to 13% of children and 10% of adults in the United States, producing a considerable negative
effect on quality of life, as well as creating a substantial economic burden. Traditional treatments for AD
include moisturizers that improve barrier integrity, topical anti-inflammatory medications, phototherapy,
systemic immunosuppressants, and short-course corticosteroids. A significant impediment of note to the
successful treatment of AD is medication adherence in patients, with adherence to topical treatments being
particularly poor. Furthermore, a complex treatment regimen adds to this notion (2). A key feature of this
research project is to create a drug delivery method that would be degradative over a week span, therefore
hopefully decreasing the complexity of currently available treatment regimens, and therefore increasing
medication adherence, especially in children.

Figure 1: Typical Presentation of Atopic Dermatitis at Various Ages from (2).
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Hydrocortisone is a topical corticosteroid, and the first one to be used in the treatment of AD. There
are now over 30 additional corticosteroid compounds approved for treatment of AD, with many others still
in clinical trials. While Hydrocortisone and other corticosteroids of the like play an important role in
treatment of AD, the potency of these drugs, as well as the varying side effects of continued local use, are
relevant to the conversation of this research project. Continued use in local areas can produce thinning of
the skin, dermal scarring, and dilated or broken blood vessels near the skin’s surface. Patients also find that
over time the effectiveness of the drug is lost, causing a greater potency level to be prescribed, further
worsening these effects (3). Hydrocortisone, however, is the corticosteroid that would have been beneficial
to the resolution of this project as a whole, had time been allowed. It will be the drug used in future studies
related to this work. The purpose of this project is to use this known effective corticosteroid, but in a novel
method that has a longer degradation time - therefore in a topical form that does not need to be applied as
often, mitigating the painful symptoms of prolonged contact with the skin.

Figure 2: Chemical Structure of Hydrocortisone from PubChem.
Ionic liquids (ILs) are a currently trending scientific topic, with applications in an incredible
number of disciplines, such as use as electrolytes, solvents, and lubricants (26). Ionic liquids are a salt in
which the ions are bulky and poorly coordinated, resulting in their being liquid below 100°C, or even at
room temperature (5). Other properties of ILs, such as viscosity and melting point, are dependent on which
precise starting materials are chosen, leading to their nickname of “designer solvents” (4). Previous
9

literature has shown that ILs are excellent candidates for facilitating Transdermal Drug Delivery, or delivery
through skin. ILs have been shown to enhance transdermal transcellular and paracellular transport, by
bypassing the barrier properties of the stratum corneum (SC), which is the current major challenge
associated with TDD (5). For this project, Choline 2-Octenoate was used as the primary IL. This consists
of Choline, the cation, and 2-Octenoic Acid, the anion, in a 1:2 ratio.

Figure 3: Structures of Choline 2-Octenoic Acid.
Nanoparticles are, like ILs, currently exploding players in modern medicine. They are materials
with overall dimensions under 100 nm. With a dimension of this size, nanoparticles can play roles in
analyses and therapies that could not be performed otherwise (6). Nanoparticles can be classified into a
number of different classes based on their sizes, shapes, or properties, with some of those categories being
polymeric NPs, metal NPs, and ceramic NPs. Nanoparticles have unique physical and chemical properties
because of their size and high surface area, with their reactivity also due to those factors (27). While
nanoparticles have use in numerous medical applications (6), their role in drug delivery is the most relevant
in regards to this paper. Every branch of medicine is interested in NPs, as they allow the potential to deliver
drugs in an optimum dosage range, thus resulting in increased efficiency of the drugs and improved
compliance by patients (27). They are currently being researched for the use in the treatment of cancer,
neurodegenerative diseases, HIV/AIDS, ocular diseases, and respiratory disease, to name a few (6).
The purpose of this particular research is to utilize nanoparticles for their applications in
transdermal drug delivery. Transdermally delivered drugs are a currently active area of research, as they
can allow for drug concentrations to be tuned to be released into the body over longer periods of time, as
well as creating less painful and invasive techniques of drug delivery. The FDA has approved numerous
TDD systems, such as a treatment for motion sickness, or systems involving nicotine, estrogen, and
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testosterone. While there are many TDD systems currently being researched, nanocarriers are a very viable
method. Nanocarrier skin penetration, while possibly being limited in intact skin, is an ideal drug delivery
method to treat diseases like psoriasis and AD, that are characterized by barrier-disrupted skin (7).
Using the senior thesis of Joel Balkaran (unpublished) that detailed his work to define a
nanoparticle that would best work in terms of size, as well as degradation time, the material Chitosan was
chosen to create the nanoparticles for this project. Balkaran’s research defined that a nanoparticle would be
needed that could be around or below 20 nm, as well as one that did not degrade quickly. His research
provided many necessary steps to the inception of this current project, namely that when creating the
nanoparticles, it is important to have Chitosan and sodium tripolyphosphate (TPP) in a 1:1 ratio.
Furthermore, he found that Chitosan in fact did not degrade over the course of a week, and the nanoparticles
were viable up to a month under refrigeration. He believed that Chitosan nanoparticles would be the most
successful material to create nanoparticles for the benefit of future research among the five materials he
tested (24).
Chitosan is derived from the exoskeletons of insects, crustaceans, and fungi making it
biocompatible and biodegradable. It is interesting because it is made from an abundantly renewable
resource, but also because it is a very compatible and effective biomaterial that can be used in many
different ways. Furthermore, Chitosan is very ecologically safe and has a low toxicity level. It is a
polycationic polymer, and has one amino group and two hydroxyl groups in its repeating glucosidic residue.
After it is refined, it has a rigid crystalline structure through inter- and intra- molecular hydrogen bonding
(8).

Figure 4: Chemical Structure of Chitosan.
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The other materials used to create the nanoparticles for this project included Glacial Acetic Acid,
TPP, and Rhodamine B. DiD dye was the original dye used to create the nanoparticles, but as Rhodamine
was more cost effective and readily available, it was used in later nanoparticle making.

Figure 5: Chemical Structures of GAA, Sodium Tripolyphosphate (TPP), and Rhodamine B dye,
respectively.
A large component of Balkaran’s research was creating a nanoparticle that was small enough in
size to be used in transdermal transport, with the size he accomplished being between 20 and 120 nm,
averaging around 70 nm (24). To create an even smaller nanoparticle, 10 nm filters were used. Dynamic
light scattering (DLS) was used to analyze the size data from these nanoparticles. Dynamic light scattering
is a technique that relies on the relationship between the scatter of light by molecules in a solution or
colloidal suspension, and their translational diffusion. DLS measures the fluctuations as an overall solution
scatters after it has been hit by a laser light, and has an intensity per molecule in a time-dependent manner
(9).

Figure 6: Graphic of how DLS operates to acquire data.
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Skin, being the largest organ of human bodies, functions to provide a homeostatic barrier. As the
skin is easily accessible and has a large surface area, transdermal drug delivery through skin can be a
major player in new medicinal methods. The skin is composed of three main histological layers:
epidermis, dermis, and hypodermis. The epidermis is 0.1-1.5 mm thick and is then further divided into 5
parts, with the squamous layer being the thickest, and the stratum corneum (SC) being composed of 10 to
30 thin layers of dead cells. Below the epidermis is the dermis, which is 1.5 to 4 mm thick and is
composed of collagen, sweat, oil glands, hair follicles, and nerve endings, to name a few. The
hypodermis, or subcutaneous tissue is the deepest layer and stores fat to act as an insulating layer (20).
For the purpose of this project, the hypodermis is removed before testing.

Figure 7: Diagram (left) representing the 3 layers of the skin, the epidermis, dermis and subcutaneous
tissue. Diagram (right) representing the layers of the epidermis, with the SC being at the top.

To assess transdermal permeation, a Franz Diffusion Cell method was utilized (Figure 8). This method
has numerous advantages including handling of tissues, no continuous sample collecting, and a low amount
of drug required for analysis. Studies using this method are furthermore easy to implement in any laboratory
(18). The apparatus itself has two primary chambers that are separated by a membrane. The product being
tested is applied to the membrane by the top chamber donor compartment. The second primary chamber,
the bottom receptor compartment contains fluid, in this case PBS was used (19). In a Franz cell, the stratum
corneum is facing the donor compartment, and the dermis is touching the receptor compartment. Many
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animal models have been tested as a substitute for human skin, including primate, porcine, mouse, guinea
pigs, and snake skins. This project utilized porcine skin. The benefit of using porcine skin is that it contains
anatomical similarities to human skin in relation to the SC, epidermal thickness, follicular structure, hair
density, and, probably most importantly, permeability. A common disadvantage of this method, however,
is that it is difficult to obtain and has a high cost (20).

Figure 8: Graphic representing the components of a Franz Diffusion Cell. Note the top donor
chamber and receptor chamber, separated by a membrane.
To measure the amount of NPs deposited into each skin layer, a fluorescent plate reader is used.
The purpose of loading the NPs with dye, then using acetone to degrade them and release fluorescence, is
found in this step, as the plate reader will measure the fluorescence of each sample, thereby giving you the
amount of NPs dispersed into each skin layer. A fluorescence plate reader, or fluorometer, is capable of
detecting and quantifying the light photos that are emitted by a fluorescent sample put into a microplate
upon education with light at a specified wavelength. They are used in various capacities, including academic
life science research, drug discovery, and clinical laboratories (21). Fluorescence itself is a physio-chemical
energy exchange in which shorter-wavelength photons are absorbed and then re-emitted as longerwavelength photons. It is a suggested means of communication in some flowers and animals, including
corals and squids, as well as humans. Fluorescence has two components, being absorption of a shortwavelength by a chemical fluorophore like a proton or carotenoid. This is known as excitation. This process
is followed by the release of absorbed energy as longer wavelength light, which is known as excitation (22).
14

Rhodamine B, the dye used in the Chitosan NPs has an excitation peak at 546 nm and an emission peak at
568 nm (23).
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CHAPTER 2: EXPERIMENTAL PROCEDURES

Materials

Choline Bicarbonate, 80% solution; 2-Octenoic Acid, 85% solution; Glacial Acetic acid, 100% solution;
Chitosan, 100% solution; Sodium tripolyphosphate (TPP), 85% solution; Rhodamine B dye; Polyethylene
glycol, 100% solution; Succinic anhydride, >99% solution; 4-dimethylaminopyridine (DMAP), .99%
solution; pyridine, 99.8% solution; N-hydroxysuccinide, 98% solution; N-(3-dimethylaminopropyl)-Nethylcarbodiimide hydrochloride (EDCL); acetonitrile; phosphate buffered saline; acetone; and methanol,
99% solution, were all purchased from Sigma Aldrich (St. Louis, MO). Pig skin was purchased from
Smokehouse Meats (Pontotoc, MS) and the Animal and Dairy Science Department Meat Lab at
Mississippi State University (Starkville, MS).

Methods

Synthesis of Ionic Liquid, Choline 2-Octenoic (1:2). To facilitate transdermal drug delivery, an ionic liquid
was synthesized, namely Choline 2-Octenoic 1:2. To create this IL, Choline Bicarbonate, with a molecular
weight of 165.19 g/mol, as well as 2-Octenoic acid, with a molecular weight of 142.20 g/mol, were used.
Using the molecular weight of the anion, 2-Octenoic acid, it was found that 10 g should be added to a round
bottom flask; the actual weight used was 10.01 g. 7.29 g of the cation, choline bicarbonate, was added
slowly. This weight was found using the molecular weight of choline bicarbonate and knowing that the mol
amount must be ½ that of the anion. The number was further corrected for the fact that the choline
bicarbonate stock solution was 80%. A stir bar was also added. The mixture was then set on an oil bath and
left overnight. On day 2, the round bottom was removed from the oil bath, the stir bar was removed, and
the mixture was placed under a 15 millibar vacuum at 60 °C for one hour. The mixture was then removed
from the rotary evaporator and put into a scintillation vial. This vial was then labelled and put into a vacuum
16

oven for 48 hours for further drying. After 48 hours, the sample was removed from the oven, and the amount
of water present was determined using Karl Fischer titration and found to be 1.2% w/w. The sample was
1
then analyzed with proton NMR spectroscopy using d6-DMSO as the solvent. H NMR (400 MHz, DMSO)
δ 6.55 – 6.43 (m, 2H), 5.71 (dd, J = 15.5, 1.7 Hz, 2H), 4.07 (s, 5H), 3.85 (td, J = 5.5, 2.6 Hz, 3H), 3.42 (dd, J = 6.0,
3.9 Hz, 2H), 3.12 (s, 9H), 2.12 – 2.02 (m, 4H), 1.37 (p, J = 7.3 Hz, 4H), 1.27 (dt, J = 10.9, 6.9 Hz, 8H), 0.86 (t, J =
6.8 Hz, 6H).

Synthesis of modified PEG solution. A modified PEG solution was created to then add to the NPs to protect
them from aggregation in the IL. A number of syntheses were attempted, but only one proved to be
effective. The first step in this was to create the modified PEG solution. This was done by first placing a
round bottom flask on a stir plate in the fume hood with no heat. A stir bar was then added, along with 2g
of PEG, 200 mg of succinic anhydride, 20 mg of DMAP, and ~40 mL of pyridine. This was topped with a
white septum stopper to avoid evaporation. This was allowed to react for 48 hours, then removed, weighed,
and added to a scintillation vial. The sample was then put into the vacuum oven overnight to allow the
sample to fully dry. It was then examined using proton NMR spectroscopy via a solution containing the
1
modified PEG and d6-DMSO as the solvent. H NMR (400 MHz, DMSO) δ 3.52 (s, 1H).

Synthesis of Chitosan Nanoparticles. The first step in this synthesis is the creation of stock solutions of the
necessary materials. Glacial acetic acid was diluted first to 2.625 mg/ml using 3.51 g of GAA in 1.337 L of
MilliQ. This was then added to Chitosan to create a 1.5 mg/mL solution of CS/GAA using 31.3 mg of
Chitosan and 20 mL of diluted GAA, creating a stock solution with an actual concentration of 1.565 mg/ml.
TPP was diluted to a 0.5 mg/mL stock solution using 54.6 mg of TPP and 100 mg of MilliQ, creating a
stock solution with an actual concentration of 0.546 mg/mL. A stock solution of Rhodamine B dye was
created in a 1 mg/mL concentration using 2mg of Rhodamine B and 2 mL of MilliQ. After stock solutions
had been made they could then be used to make the NPs themselves. After numerous tests it was discovered
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that NPs with 4% dye showed the most promise for later skin trials, and this is what was used. A 250 mL
round bottom flask was used to create the NPs, after first being washed 3x each with acetone and then
MilliQ water. It was wrapped in aluminum foil and placed on a stir plate with no heat. 6.39 mL of the
CS/GAA solution was added to the round bottom, along with a stir bar. To create a 4% dye concentration,
1.252 mL of the Rhodamine stock was added. Both of these items were added using a 1 mL micropipette.
Then, using a glass pasteur pipette, 6.39 mL of the TPP stock solution was added dropwise, allowing at
least 5 seconds between each drop to allow for proper dispersion. The stir was set to 1100 rpm, and this
was allowed to sit for 4 hours.

Synthesis of modPEG/CS Nanoparticles. On the same day that the NPs were made, and at the same time as
their inception, another reaction was begun as well. In a separate round bottom flask also covered in foil
under the fume hood, 0.1 g modPEG solution, 0.007 g NHS, 0.011 g EDCl, and 5 mL of acetonitrile were
added in along with a stir bar. The round bottom was then placed on a stir plate with the stir on and heat off
and capped with a white septum stopper to avoid evaporation. This was also allowed to sit for 4 hours. After
4 hours, the NP solution was removed from the stir plate, then added dropwise to the modPEG solution.
After all of the NPs had been added, the round bottom was stoppered with a white septum stopper and the
two solutions were allowed to combine for 48 hours. After 48 hours they were added to a scintillation vial
and analyzed under DLS, after having been filtered with a 100 nm syringe filter. IL was also added to the
filtered NPs and analyzed via DLS. A method was then needed to degrade the nanoparticles, as it was
shown that they did not emit the correct amount of fluorescence while in tact. DLS analysis showed that
addition of acetone was the best way to degrade the particles.

Pig Skin Testing. The protocol for pig skin test (page 40) was then used to test the IL/NP solution to
determine if the hypothesis of NPs needing IL to travel through the skin was correct. Filtered NPs were
dessicated overnight the night before they were used in the trial to remove water from them and create a
more concentrated NP solution. 300 uL of a 150 uL IL/ 150 uL MilliQ / 100 uL NP solution was added to
18

the top of the pig skin, with a control in each trial using only MeOH/PBS. A control trial using 300 uL of
300 uL milliQ and 100 uL of NPs was also done. On day 2 of the protocol, as each sample (A1-3, SC 1-10,
E, D) was added to 3 mL of MeOH/PBS, 50 uL of acetone was also added to the scintillation vial to degrade
the NPs and release the fluorescence of the Rhodamine dye. On day 3, 100 uL of each sample, along with
100 uL of a calibration curve containing serial dilutions of the stock solution, was added to a plate and
analyzed using a fluorescence plate reader with wavelengths of 570 and 540.
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CHAPTER 3: RESULTS AND DISCUSSION

Synthesis of Ionic Liquid: Choline 2-Octenoic (1:2).
The first step in beginning this project was to synthesize an Ionic Liquid that would act as the carrier of
NPs for transdermal drug delivery. Choline 2-Octenoic 1:2 was chosen as the IL suitable for this task
because of its established efficacy as a permeation enhancer [Adv Mat ref; Tanner 2019]. The IL was
synthesized by combining choline bicarbonate with 2-octenoic acid in a 1:2 molar ratio. This generates a
viscous liquid product, with water and carbon dioxide as byproducts. The water is removed via rotary
evaporation and vacuum oven drying. Proton NMR spectroscopy was conducted to confirm successful
synthesis of the IL (Figure 9). The NMR results were characterized by normalizing the peak at 3.12 ppm
to 9, as we know this is the nitrogen group on Choline, which has 9 protons surrounding it. Labelled in the
NMR data are the peaks that correspond to each carbon in both the molecule of Choline and 2-Octenoic
Acid. The peak at 2.5 ppm represents the solvent used, d6-DMSO. The large peak at 4.07 ppm does not
correspond to any C group present in the chemical structures of either Choline or 2-Octenoic Acid, and is
theorized to be a present due to water in the sample. Note that while the original IL was made by me as a
means of learning how to create ILs, the synthesized IL that was used in actual testing with pig skin was
created by fellow researcher Claylee Chism.
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Figure 9: Written characterization and NMR spectra of Choline 2-Octenoic 1:2.

Synthesis of Chitosan Nanoparticles.
Chitosan was chosen based on knowledge from previous research to be the most suitable material for
creating a NP that would be small enough to enter the layers of the skin, as well as tough enough to not
degrade over the course of a week. The steps for synthesizing this include addition of Rhodamine B dye
to a CS/GAA stock solution, then the dropwise addition of TPP to cause polymerization under stirring
conditions. This mixture was allowed to sit for 4 hours, before being removed, filtered, and analyzed by
DLS. In beginning syntheses of Chitosan nanoparticles, the dye used was DiD. Beginning data provided
by DLS is reflective of that. Furthermore, provided data of NPs combined with the modified PEG
solution also have DiD as the dye used. The first hurdle that needed to be overcome was creating a
Chitosan NP that would be small enough to pass through the layers of the skin. The target size was below
10 nm.
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Figure 10: Initial data of NPs, aiming a size below 10 nm.
As is shown in Figure 10, using a micron filter, the target size was reached. The nanoparticles
themselves showed some aggregation around 1000 nm, potentially due to contamination of micropipettes
in the laboratory. This, however, proved that NPs could be created and filtered to reach a size below 10
nm. At this point, IL was added in both a 25% and 50% ratio to NP. This method proved highly
unsuccessful, and the NPs aggregated, or altogether died. Here, using literature, it was discerned that a
modified PEG could be created that would add a carboxylic acid group to the PEG, and thus allowing the
PEG to provide a coat for the NP by attaching to an amine group on Chitosan when solvated in IL. The
challenges of creating this modified PEG are detailed in the below section.

Synthesis of Modified PEG solution.
A significant portion of this project included the fact that once the Chitosan nanoparticles were
solvated in ILs, aggregation occurred and the nanoparticles were no longer viable for use. To combat this,
a modified PEG solution was added to the NPs to give them a coating to resist aggregation. Previous
literature suggested that this method would be beneficial, but no literature yet existed on how to achieve a
modified PEG solution that would work in this way with already assembled nanoparticles..
PEG, or polyethylene glycol, is a biocompatible, synthetic, and hydrophilic polyether compound
that is characterized by being non-toxic, odorless, and highly soluble in water. PEG has a number of
applications in the medical industry, as it lends itself to numerous pharmaceutical and biomedical

22

applications. The most common current application of PEG is as a laxative, but it is also used in many
pharmaceutical creams, ointments, and medical solvents. It can be used as an inactive substance that acts
as a drug vehicle, and it can be used in systemic drug delivery by adding a surface coating to nanoparticles,
as was done in this project (10).

Figure 11: Chemical structure of PEG.
Multiple syntheses were attempted and failed to create a modified PEG solution that contained first
a carboxylic acid group. A protocol was finally found that created the desired product, and this included
adding PEG to succinic anhydride, DMAP (4-dimethylaminopyridine), and pyridine at room temperature
for 48 hrs, under stirring and covered conditions. Succinic anhydride has a molecular weight of 100.07
g/mol and appears as a colorless white crystal in its solid state (14). DMAP has been shown to be a highly
efficient catalyst for acylation reactions (15). Lastly, pyridine is a basic N-heterocyclic compound that acts
as a nitrogen donor ligand. Pyridine has a molecular weight of 79.10 g/mol and appears in liquid form (16).

Figure 12: Chemical structures of succinic anhydride, DMAP, and pyridine, respectively.
When this product was formed, it was added to N-hydroxysuccinimide (NHS), N-(3Dimethylaminopropyl)-N′- ethylcarbodiimide hydrochloride (EDCl), and acetonitrile. NHS is a
hydroxylated succinimide that is commonly used in the activation of carboxylic acids to NHS-esters, that
promotes coupling with nucleophiles. It has a molecular weight of 115.09 g/mol, and is a solid in its
natural state (11). EDCl is a white powder in its solid state and has a molecular weight of 191.70 g/mol. It
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is a water soluble condensing agent, and has been used to previously modify the cell surface of E. coli to
covalently couple substances (12). Acetonitrile has many uses, including as a solvent, in lithium batteries,
and spinning fibers. It is most often found in air from automobile exhaust, as well as from manufacturing
facilities. It is a volatile organic compound and appears as a colorless liquid (13).

Figure 13: Chemical structures of NHS, EDCl, and Acetonitrile, respectively.

Figure 14: Supposed chemical synthesis of fully modified PEG, the final result being how the modPEG is
added to NPs.
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Figure 14 shows the supposed chemical synthesis of fully modified PEG. The top most reaction is
representative of what occurs in the first 48 hours of the synthesis, and what is shown on the NMR data
below. EDCl and NHS are then added in a separate 4 hour reaction, EDCl to service as a cross linker, so
that NHS can attach to PEG and add an amine group - the intended final goal. The final finished product,
labelled above as modPEG, is what is then used to react with the NPs and provide their coating.
NMR spectroscopy was then performed to confirm if the desired product had been successfully
made, this is shown in Figure 15. Looking at the structure of PEG, the peak around 3.5 ppm represents the
terminal methyl group, and the peak around 3.3 ppm represents the interior carbon. The peak at 2.5 ppm is
due to d6-DMSO, the solvent used to run NMR spectroscopy. Succinic anhydride, however, also shows
spectra around 2.5 ppm, so the amount of d6-DMSO used could be covering up the peak that would
represent the addition of succinic anhydride. The created solution worked in aiding NPs when solvated in
IL, so it can be assumed that the carboxylic acid from succinic anhydride was successfully added.

Figure 15: NMR data of modified PEG to the point of addition of succinic anhydride.
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Synthesis of Chitosan Nanoparticles.
Once the 4 hours were completed, the modPEG solution and the NPs were combined and allowed to sit
under stir for 48 hours. Figure 16 below shows the DLS data of creating the modPEG/NP mixture, as well
as filtering it with a micron filter. The aggregation around 1000 nm can once again be attributed to
contamination of micropipettes in the lab.

Figure 16: DLS data of Chitosan NPs after being coated with modPEG.

The next step was to add IL to the NP/modPEG solution to test if the modPEG truly worked in coating
the NPs and therefore preventing aggregation once solvated with IL. Figure 17 shows that this was
successful, as there is no aggregation shown around the 1000 nm mark, and the entire concentration of
NPs is below 10 nm, that being the target size.
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Figure 17: DLS data presenting Chitosan NPs/modPEG solution solvated in 50% IL.

After an unsuccessful pig skin trial using the modPEG/NP/IL solution shown in Figure 17, which is not
provided here due to relevancy, it was shown that the amount of DiD used was not enough to provide the
fluorescence needed to analyze data of NPs through skin layers. It was then decided that Rhodamine B,
because of its availability and cost, would be used to provide fluorescence to future NPs. Numerous
concentrations of dye were tested, being 1.5%, 2%, and 4%. To find the amount of dye necessary for each
concentration, the percentage was calculated from the amount of Chitosan in the original stock solution,
being 31.3 g. Therefore, for the 1.5% concentration, 0.4695 mL of Rhodamine stock was added, for the
2% concentration 0.6 mL of Rhodamine stock was added, and for the 4% concentration 1.252 mL of
Rhodamine stock was added. Shown in Figure 18 is the DLS data of each dye concentration amount.
Prior to running DLS the NPs were filtered through a micron filter to reach target size. The DLS data of
the NPs prior to filtering is not shown, once again due to relevancy, being that the NPs would need to be
filtered before testing on pig skin.
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Figure 18: DLS data of Chitosan NPs with differing Rhodamine dye concentrations, 1.5% (top), 2%
(second from top), 4% (third from top), and a repeat of 4% with a subsequently made batch of NPs
(bottom).

After analyzing the DLS data, it was decided that 4% would be the best candidate for use in future work.
It contained the most dye, so therefore the most fluorescence, but also looked the most stable and had the
greatest concentration of NPs below 10 nm. As this was the target size, this is why 4% was chosen. A
calibration curve is shown in Figure 19 to demonstrate the fluorescence vs concentration of the 4%
Rhodamine NPs. As the curve had an R^2 value of 1, the curve is very accurate in regards to the
generated data.
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Figure 19: Calibration curve of concentration vs fluorescent intensity of 4% rhodamine NPs.
The next portion would be adding IL to the 4% Rhodamine NPs, which would create a less stable NP.
Based on DLS data, that is what occurred (Figure 20). The NPs, however, were still present within the
target size needed to enter skin, that being around 100 nm, but especially below 10 nm. To create a NP/IL
solution that was more stable and had a higher concentration of NPs within the target range, a vacuum
filtration method was implemented before IL addition to remove water from the NPs, so that the water
would not react with the IL. Once again, this method proved successful. Numerous methods were
attempted and failed prior to reaching this success, however. The first attempted method of removing
water was to create a solution of 800 µL NP and 150 µL IL, then put this solution on the rotary
evaporator. This method failed. Next the same volume of NP/IL was allowed to dessicate overnight in a
vacuum desiccator. This method also failed, resulting in a large peak at 1000 nm according to DLS data,
insinuating that aggregation had occurred. Finally it was shown that desiccating just the volume of NPs
overnight and then adding IL was the most effective method. It is important to note that the NPs should
not be left longer than overnight, as anything longer results in evaporation of NPs themselves. Figure 21
shows the results of vacuuming just NPs, then adding IL.
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Figure 20: DLS data of addition of IL to the 4% Rhodamine NPs.

Figure 21: DLS data of NPs with IL following vacuum method.
Knowing that Rhodamine contained enough fluorescence to show data in a skin test, a subsequent
failed test gave us the knowledge that the NPs would need to be killed to release their fluorescence before
a plate read could be done. Acetone was chosen as the medium for killing NPs, at varying liquid
concentrations in mL. 50 mL proved successful in effectively killing the NPs, as is shown in the DLS data
from Figure 22. The percentage of NPs decreased significantly compared to Figure 21, as did the
stability of the NPs. With the knowledge that the NPs could be killed to release their fluorescence, as well
as the knowledge that the NPs were stable in IL post vacuuming, the solution consisting of IL/NPs could
be applied to porcine skin testing.
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Figure 22: DLS of data of NP with IL after addition of Acetone.

Pig skin testing.
Lastly, porcine skin testing was conducted to test the effectiveness of the NP/IL solution. The purpose of
doing this is because, as previously mentioned, porcine skin is very similar to human skin in terms of
epidermal thickness, SC makeup, and permeability. Continuing to review information provided by
Balkaran’s thesis, when viewing the results provided by the Franz cell, 5 layers are examined. The first
layer that is tested is the donor fluid, in which we hope to find no NPs, indicating they have all entered the
skin. Second we observe the SC, which should have some NPs, but less than any other skin layer. We
then have the epidermis which should have more NPs than the SC, but less than the dermis. The dermis is
analyzed, and this is where the majority of the NPs should be located. Ideally, the last layer, the acceptor
fluid, should have no NPs, showing that the particles are within the skin and not being deposited into
what would be the bloodstream (24). The solution applied to the porcine skin was made up of the IL
Choline 2-Octenoic 1:2, DIH2O, and 4% Rhodamine Chitosan NPs that had been filtered and vacuumed.
Following the skin protocol listed under Protocols, all steps remained the same, except the fact that during
Day 2, 50 µL of acetone was added to the scintillation vials containing the skin samples to degrade the
NPs. A separate control test was done containing just NPs and DIH2O to prove the theory that IL is
necessary to carry the NPs through the layers of the skin. Figure 23 shows a calibration curve

32

representing the data of the fluorescence intensity of the Rhodamine versus the concentration of NPs in
the IL sample being tested. The data represented here shows an R^2 value of 0.9926, which indicates that
the data is accurate.

Figure 23: Calibration curve of fluorescent intensity vs concentration of NP/50% IL solution, with a
slope of 2 x 108 and an R2 of 0.9926.
Using the data provided by the calibration curve in Figure 23, and the knowledge of how to interpret said
data from Day 3 of the Protocol for Pig Skin Testing, a graph was produced comparing the results of both
the test containing IL and the test containing no IL. That is represented in Figure 24.

Figure 24: Graph representing data from both the IL test (red) and the control test containing just water
(blue).
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The graph in Figure 24 shows, in blue, the results of the control trial of just NPs and water, and, in red,
the results of the trial using NPs solvated in IL. A t-test of each of the layers of the skin gives the results
of: 0.0005161 for the SC, 0.06198 for the epidermis, 0.00397 for the dermis, and 0.001626 for the
accepter fluid. These numbers show that the difference in the number of NPs in each layer is statistically
significant, excluding the epidermis. T-test values should be below 0.05, and the t-test for the epidermis
was above this number. Overall, however, the results from each layer are significant, thus proving that IL
is necessary for NPs to successfully reach the layers of the skin. This is beneficial for the project as a
whole, as going forward it can be known that IL does assist in transdermal drug delivery. The next steps
in this project would be to encapsulate hydrocortisone in the Chitosan nanoparticles, and then solvate this
in IL to then test on porcine skin. If this proved successful, testing could then move on to mouse testing,
and eventually the development of a drug that could be used by humans.
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CHAPTER 4: CONCLUSION

Drug delivery methods today range from intravenous, topical, oral, and so many others. The
purpose of this project was to create a method that was not only easy to apply at home, but has a long
delivery time, as to be beneficial to children or people with busy lives who do not want the hassle of
constantly applying/taking medication. To get to this point, the project will need to be continued by a
future researcher. However, this project did jump many of the hurdles necessary to reach said goal.
In an effort to create a method of drug delivery through skin involving ionic liquid solvated
nanoparticles, data compiled by past researcher Joel Balkaran involving the synthesis of Chitosan
nanoparticles was crucial to the inception of the project. A provided template also gave the instructions
for creating the Ionic Liquid necessary to apply to the nanoparticles, that being Choline-2-Octenoic 1:2.
Moving forward, it was shown by means of DLS that solvating the bare nanoparticles in IL resulted in
the aggregation of the particles. A procedure then needed to be developed to provide a layer of protection
to the nanoparticles to allow the IL to solvate the particle without inducing aggregation.
Multiple protocols were attempted and failed to create a modified version of polyethylene glycol,
PEG, that would be viable to coat the nanoparticles and provide protection from the IL. A simple method
was then developed to create a version of the PEG with a carboxylic acid group that could be grafted
covalently to the amine groups on the chitosan nanoparticles. Creation of the nanoparticles, addition of
the modified PEG, and a 48 time span to allow the two to completely react proved successful.
Incorporation of the IL to the now modified PEG NPs proved successful via DLS, and it was shown that
the NPs could now survive being solvated in the IL and would therefore be operational for means of tests
using pig skin. However, it was further shown that these methods created a NP with a strong capacity for
life, and in order to release the dye encapsulated in the NPs, acetone must be added to degrade the particle
and release the fluorescence of the dye. The original dye used was DiD, but as it was hard to work with
and did not show enough fluorescence, Rhodamine became the dye of choice in these tests at a 4%
concentration. It was also discovered that the NPs must be vacuumed in a vacuum desiccator prior to IL
35

addition to remove any excess water from the NPs to increase their concentration in the IL. It is important
to note here that all nanoparticles used to make such discoveries were filtered with a micron filter to reach
a target size of around 100 nm, with an aim of below 10 nm.
The addition of this modPEG/NP/IL solution to pig skin was then used as the determining factor
of the viability of these trials and of this compound as a reasonable method for drug delivery. As the
results from the trial in which the NPs were solvated in IL was statistically significantly different from the
control trial, it was shown that IL is beneficial for transdermal drug delivery. Overall, this shows that the
results of the porcine skin trial were successful, and testing can move towards encapsulating
hydrocortisone in the Chitosan NPs and further testing can be done in porcine skin, and eventually animal
trials and human trials.
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PROTOCOLS

PROTOCOL FOR PIG SKIN TESTING
A.Preparation of the Diffusion Cells. (Day 1)
1. Weigh out test article and combine with IL (insulin and most other proteins are good at 1mg/mL).
The standard loading for the donor chamber is 300 ul. The test article must be fully dissolved, or
at least well and evenly suspended in the IL. Use the sonicator and the vortexer. 5 minutes on
high sonication along with some vortexing and smashing any large pieces with a spatula against
the tube wall to break them up usually works.
2. Spray the bench and tools with 70% Ethanol.
3. Remove one skin strip from the -80 C freezer and allow it to thaw fully without unwrapping or
otherwise disturbing it.
4. Pick a region of the skin sample to start with. Often the center is good. Thin sections with less
visible pores are ideal.
5. Use the 36 mm punch and the hammer to cut out a disk. You can use a scalpel to remove any
connective tissue remaining.
6. Give the pig disk a haircut in the center, where the donor chamber will sit. Be careful not to cut
the skin.
7. Remove any subcutaneous fat, being careful not to cut into the dermis.
8. Wash disk with PBS (ca. 1 mL) and pat dry with Kimwipes. Check that there is no foil or other
debris on the disk.
9. To set up the Franz diffusion cells, place a stirrer bar in the acceptor chamber and fill with PBS
until overflowing.
10. Add skin, place donor chamber on top of skin, and clamp (to finger tight). Using forceps, gently
pull the skin edges to make sure there are no folds.
11. Turn the chamber upside down to remove any air bubbles through the side arm. There should be
no bubbles, as this will affect the transport.
12. Add 1 mL of PBS to the donor chamber.
13. Test conductivity by turning the waveform generator on and adjusting the settings. Frequency =
100 Hz, amplitude = 100 mV. Plug in the voltmeter (output channel on the waveform generator),
turn it on, and set it to measure A. Clean the rod and probe with a Kimwipe (they can get rusty).
Put the rod in the side arm and the other probe in the PBS on top of the skin.
14. If the sample returns a reading of less than 10A (preferably around 5) it can be used.
15. Record the conductivities for the skin samples that were successful and randomly assign
treatments.
16. Remove the 1 ml of PBS from the donor chamber without touching the skin and place the
diffusion cells in the oven to warm up (37 C).
17. Remove the cells from the oven, and place 300L of IL - test article onto skin, ensuring that the
whole surface is covered. Avoid touching the skin with the pipette tip.
18. Seal top to donor chamber with parafilm followed by foil. Label the top of the foil with the test
article/sample.
19. Ensure the level of liquid in the side arm is approximately at the level of the skin.
20. Place an Eppendorf tube onto the side arm like a hat, to reduce evaporation.
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21. Check the clamp – it should be finger tight. It will have loosened up in the oven. Don’t
overtighten, as that can damage the skin.
22. Return the cells to the oven at 37 C for the prescribed time (24, 48hrs).
B. Extraction of the drug into Methanol/PBS (Day 2)
1. Spray the bench and tools with 70% Ethanol.
2. Use a piece of foil to collect any waste.
3. Label 8 vials per sample – the Acceptor fluid (A1,2,3), the first SC strip (SC1), SC 2–5, SC 6 –
10, Epidermis (E), and Dermis (D).
4. Put 3 mL of 50% Methanol/PBS into each vial, along with 50 µL of acetone.
5. Spray everything with ethanol in between samples. Start with the control (i.e. PBS only) sample
to further avoid contamination of subsequent samples.
6. Remove diffusion cells from the oven and remove the foil and parafilm.
7. Gently remove leftover solution from the donor chamber using a pipette – try to do this from the
side to prevent damaging the central skin. Take 50L of one of the solutions and put it aside.
8. Wash skin with 1 mL PBS two times, flushing the PBS across the skin by pipetting up from one
side of the donor chamber and dispensing on the other side several times. Remove as above.
9. Disassemble cells and place skin on a cutting board, patting the top and bottom of the disc gently
with a Kimwipe to remove excess liquid. Do not wipe the top – this can disturb the stratum
corneum.
10. Distribute the acceptor fluid into the three vials marked for this purpose.
11. Place the used cells in buckets with warm, soapy water and leave to soak.
12. Use the 15 mm punch and hammer to remove the central portion of the skin.
13. Take about an inch of scotch tape and press it gently to the top of the skin, being careful not to
remove the whole epidermis when it is removed. Place the tape into the vial marked ‘SC1’.
14. Repeat the tape stripping nine more times, placing the 2nd to 5th strips in the vial marked ‘SC25’, and the 6th to 10th strips in the vial marked ‘SC6-10’.
15. Remove the epidermis from the dermis and place it in the vial marked ‘E’. In some cases, the use
of a scalpel will be necessary to separate the two.
16. Use the 4 mm punch and hammer to remove three circles of dermis.
17. Use a scalpel to halve each of the circles and place them into the vial labelled ‘D’.
18. Place all of the vials onto a shaker at RT overnight.
19. Spray all of the boards and tools with Ethanol.
C. Plate Reading (Day 3)
1. Take 1 ml of the liquid (not the solids) from each sample vial and centrifuge at 14000g for 5 min
in an Eppendorf tube.
2. Pipette 250 uL of the liquid sample from the tube (stay away from the tissue debris) into one well
of a black 96 well plate.
3. Prepare standards to provide a calibration curve using serial dilution.
4. Note the excitation and emission wavelengths of your fluorophore.
5. Use the SpectraMax Plate reader to obtain raw fluorescence data. Be sure to run the read height
adjustment each time.
6. Divide the raw fluorescence by the gradient of the calibration curve to get sample concentration
e.g. mg/ml.
7. To get mass in solvent: Multiply conc x 3 ml
8. To get mass in acceptor solvent: Multiply conc x 3 ml
9. To get mass in tissue or acceptor sample: a. SC – same as in solvent, b. Epidermis – same as in
solvent, c. Dermis – Multiply x 3 (3 x 5mm diameter discs are 1/3 the total 15 mm sample area),
d. Acceptor – same as in solvent
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10. To get transport (mass/area): Divide all mass numbers by 1.77 cm2 (Area of the 15 mm diameter
punch)
D. Finishing up
1. Dispose of the vials in the solid glass waste.
2. Fish the stir bars out of the wash bucket. Wash well and rinse with DI water and dry.
3. Wash the diffusion cells with soap and hot water. Use bristle brushes to scrub all pieces.
4. Rinse all diffusion cell pieces in DI water and lay on paper towels to dry
PROTOCOL FOR CHITOSAN NANOPARTICLES/4% RHODAMINE
1.
2.
3.
4.
5.

2.625 mg/ml of glacial acetic acid (GAA) was prepared by diluting pure GAA in MilliQ water.
Chitosan (CS) was dissolved in the 2.625 mg/ml GAA solution at a concentration of 1.5mg/ml.
Sodium tripolyphosphate (TPP) was dissolved in MilliQ water at a concentration of 0.5mg/ml.
6.39 mL CS/GAA was added to a clean RBF.
1.252 mL Rhodamine stock solution was added to RBF, along with a stir bar, then magnetic
stirring was turned on at 1100 rpm.
6. 6.39 mL TPP was added to RBF drop-wise using a glass pipette, allowing a minimum of 5
seconds between each drop to give the TPP time to disperse. This caused gelation of the CS
polymer.
7. Once all of the TPP was added, the RBF was covered in aluminum foil and allowed to sit for 4
hours.
8. After four hours, the NPs were removed from the RBF and kept in an aluminum foil covered scint
vial in the refrigerator.
PROTOCOL FOR modPEG
1.
2.
3.
4.
5.
6.
7.
8.

Get and clean RBF and put on a magnetic stir plate in a fume hood.
Add a stir bar.
Add 2g PEG.
Add 200 mg Succinic anhydride.
Add 20 mg DMAP.
Add ~40 mL pyridine.
Plug top of RBF with a white septum stopper, and allow it to sit on stir for 48 hours.
After 48 hours remove from stir and put in a scintillation vial. Put the scint vial in the vacuum
oven overnight. Measure mass.
PROTOCOL FOR ADDITION OF modPEG TO CHITOSAN NANOPARTICLES

1.
2.
3.
4.
5.
6.

Put a RBF under the fume hood on a magnetic stir plate and add a stir bar.
Add 0.1 g modPEG.
Add 0.007 g NHS.
Add 0.011 EDCl.
Add 5 mL Acetonitrile.
Add a white septum stopper and allow it to sit for 4 hours.
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7. Make Chitosan NPs at the same time following the above protocol. The four hours should end at
the same time.
8. After 4 hours, pipette contents of NP solution into modPEG solution dropwise using a glass
pipette allowing 5 seconds in between each drop. Under fume hood.
9. Cover RBF with foil and use a white septum stopper. Allow this to sit for 48 hours.
10. After 48 hours remove from RBF, put in an aluminum foil covered scintillation vial, and store in
the fridge.
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